A Phase II Study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed diffuse large b-cell lymphoma (DLBCL)

Researchers

Grant status

Active

Grant start date

01/07/2017

Grant funding

  • 2016: $87,470 from Australasian Leukaemia and Lymphoma Group
  • 2019: $52,063 from Australasian Leukaemia and Lymphoma Group
  • 2020: $52,063 from Australasian Leukaemia and Lymphoma Group
  • 2021: $52,063 from Australasian Leukaemia and Lymphoma Group

Updated:  02 December 2022 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers